Reyataz Sales Data
| Rank 75 | Current sales rank, all U.S. Pharmaceuticals. |
Last updated: February 2014 (updated quarterly).
The following data shows Reyataz U.S. retail sales in Q4 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q4 2013 | 75 ( 2) |
$217,793 | -1.38% | 231 | -2.53% |
| Q3 2013 | 73 (8) |
$220,847 | -7.09% | 237 | -9.20% |
| Q2 2013 | 65 (1) |
$237,689 | -0.17% | 261 | -0.38% |
| Q1 2013 | 64 (2) |
$238,094 | 0.18% | 262 | -5.42% |
| Q4 2012 | 62 ( 1) |
$237,659 | 0.65% | 277 | 0.36% |
| Q3 2012 | 63 (2) |
$236,127 | 1.20% | 276 | -1.08% |
| Q2 2012 | 65 (6) |
$233,330 | -2.02% | 279 | -1.76% |
| Q1 2012 | 71 (1) |
$238,151 | 1.45% | 284 | -1.73% |
| Q4 2011 | 72 (2) |
$234,758 | 3.45% | 289 | 3.21% |
| Q3 2011 | 70 (1) |
$226,939 | -2.22% | 280 | -1.75% |
| Q2 2011 | 71 (5) |
$232,090 | 1.96% | 285 | 1.79% |
| Q1 2011 | 76 | $227,624 | n/a | 280 | n/a |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
